Your session is about to expire
← Back to Search
Radioisotope Therapy
177Lu-DOTA-EB-TATE for Neuroendocrine Cancer
Phase 1
Recruiting
Led By Lisa Bodei, MD, PhD
Research Sponsored by Molecular Targeting Technologies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
This trial is testing a new targeted radiation therapy for patients with advanced or hard-to-remove GEP-NETs. The therapy uses a radioactive substance that binds to cancer cells and delivers radiation directly to them.
Who is the study for?
Adults over 18 with advanced, inoperable well-differentiated neuroendocrine tumors (GEP-NETs) that are positive for somatostatin receptors can join this trial. They must have measurable disease, agree to use contraception, and have not had certain recent treatments or other cancers. People with severe organ dysfunction, active infections like hepatitis or HIV, uncontrolled diabetes, or who are pregnant/breastfeeding cannot participate.
What is being tested?
The trial is testing the safety and dosage of a new treatment called 177Lu-DOTA-EB-TATE in patients with specific types of neuroendocrine tumors. It's an early-phase study focusing on how well patients tolerate the drug and how it distributes in their bodies.
What are the potential side effects?
Potential side effects may include kidney damage due to radiation exposure from the treatment as well as typical symptoms associated with cancer therapies such as nausea, fatigue, and blood cell count changes. The exact side effects will be monitored closely given this is a Phase I trial.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
1Treatment groups
Experimental Treatment
Group I: Peptide Receptor Radionucleotide Therapy (PRRT)Experimental Treatment2 Interventions
The treatment regimen will consist of a single-dose intravenous administration of 177Lu-DOTA-EB-TATE per 6-week cycle, for a total of 2 cycles. The dose per cycle will be fixed for each patient and will be escalated in 3 different dose levels, from 50 mCi to 150 mCi (1.85 -5.55 GBq). Each dose of 177Lu-DOTA-EB-TATE will be administered in association with intravenous renal protective amino acid solutions.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Neuroendocrine Tumors (NETs) include targeted radiotherapy, such as 177Lu-DOTA-EB-TATE, which works by binding to somatostatin receptors that are overexpressed on the surface of NET cells. This allows the radioactive component, Lutetium-177, to deliver targeted radiation directly to the tumor cells, minimizing damage to surrounding healthy tissue.
This mechanism is crucial for NET patients as it provides a more precise treatment option, potentially leading to better outcomes and fewer side effects compared to traditional therapies. Other systemic treatments, like somatostatin analogs (e.g., octreotide, lanreotide), work by inhibiting hormone secretion and tumor growth, while molecularly targeted therapies and chemotherapy aim to disrupt specific pathways involved in tumor proliferation.
Find a Location
Who is running the clinical trial?
Molecular Targeting Technologies, Inc.Lead Sponsor
2 Previous Clinical Trials
72 Total Patients Enrolled
ClinSmartIndustry Sponsor
1 Previous Clinical Trials
18 Total Patients Enrolled
Lisa Bodei, MD, PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
2 Previous Clinical Trials
60 Total Patients Enrolled
2 Trials studying Neuroendocrine Tumors
60 Patients Enrolled for Neuroendocrine Tumors
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't used somatostatin or its analogues in the last 4 months.I had local therapy over 4 weeks ago.I have tumors that cannot be treated with local therapies before starting the treatment.I have no other cancers except for possibly non-melanoma skin cancer or treated cervical carcinoma in situ.My bone marrow is not working well.My brain metastases have been treated and are now stable.I cannot stop my octreotide treatment for 24 hours before and after receiving 177Lu-DOTA-EB-TATE.My last surgery was more than 6 weeks ago.I have had more than 4 treatments with 177Lu-DOTA-TATE.I am not pregnant or breastfeeding.I am 18 years old or older.I have severe urinary incontinence making certain cancer treatments unsafe for me.I haven't had cancer treatment or experimental drugs in the last 4 weeks or longer.I am still recovering from a major surgery or injury, or expect to have major surgery soon.My liver is not working well.My kidney function is reduced with a creatinine level over 1.7 mg/dL.I do not have any serious infections like HBV, HCV, HIV, or AIDS.I am able to care for myself but may not be able to do active work.I have not been treated with 177Lu-DOTA-TATE or had no cancer growth for 12 months after treatment.My kidneys are functioning well.My scan shows high levels of certain receptors in at least one cancer lesion.I've had radiation therapy that affected more than a quarter of my bone marrow.Over 80% of my liver is affected by cancer.My tumor is a confirmed, inoperable neuroendocrine tumor of the GI or pancreas.My cancer has spread to over 25% of my bone marrow.My cancer is a type of aggressive neuroendocrine tumor.My side effects from previous treatments have mostly gone away.My neuroendocrine tumor is classified as grade 1, 2, or 3.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.
Research Study Groups:
This trial has the following groups:- Group 1: Peptide Receptor Radionucleotide Therapy (PRRT)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger